BLCM
-6.68%(-0.01)
Open
0.08
Prev Close
0.08
Day High
0.09
Day Low
0.07
Volume
6,059
Avg Volume
28,581
52W High
1.31
52W Low
0.06
ANALYST COVERAGE8 analysts
BUY
Buy
788%
Hold
113%
7 Buy (88%)1 Hold (13%)0 Sell (-1%)
Full report →
PRICE
Prev Close
0.08
Open
0.08
Day Range0.07 – 0.09
0.07
0.09
52W Range0.06 – 1.31
0.06
1.31
1% of range
VOLUME & SIZE
Avg Volume
28.6K
FUNDAMENTALS
P/E Ratio
-0.1x
Not profitable
EPS (TTM)
Div Yield
No dividend
Beta
0.73
Low vol
TECHNICAL
RSI (14)
30
Bearish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 24
DEx-Dividend
In 90 days
Aug 21
PDividend Pay
In 108 days
Sep 8

BLCM News

About

bellicum pharmaceuticals, located near the houston medical center, is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. we are developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (hsct) and car t cell therapy. we are dedicated to creating an exceptional work environment and are passionate about working to provide innovative new treatment options that can improve health and save lives.

Industry
Pharmaceutical Preparation Manufacturing
CEO
Richard Fair
Alan K. SmithChief Scientific Officer
Charles S. GrassPrincipal Accounting Officer
David MaggioChief Executive Officer
Joseph SenesacSenior Vice President of Technical Operations & Quality